{"id":496219,"date":"2021-05-20T07:03:32","date_gmt":"2021-05-20T11:03:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2021-05-20T07:03:32","modified_gmt":"2021-05-20T11:03:32","slug":"neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting<\/b><\/p>\n<p>ROCKVILLE, Md.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fneoimmunetech.com%2F&amp;esheet=52432801&amp;newsitemid=20210520005304&amp;lan=en-US&amp;anchor=NeoImmuneTech%2C+Inc.&amp;index=1&amp;md5=de3bb14bf98e40b7d7409d5666c6f6ae\">NeoImmuneTech, Inc.<\/a> (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company\u2019s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021. The data come from clinical studies evaluating NT-I7, a novel long-acting human IL-7, 1. in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) as a treatment for advanced solid tumors, and 2. given concurrently with adjuvant chemotherapy in patients with high-grade gliomas.\n<\/p>\n<p>\nDetails related to the poster presentations are as follows:\n<\/p>\n<p>\nTitle: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetinglibrary.asco.org%2Frecord%2F196050%2Fabstract&amp;esheet=52432801&amp;newsitemid=20210520005304&amp;lan=en-US&amp;anchor=Safety%2C+Pharmacokinetics%2C+Pharmacodynamics+Profiles+and+Preliminary+Antitumor+Activity+of+Phase+1b%2F2a+Study+of+NT-I7%2C+a+Long-Acting+Interleukin-7%2C+plus+Pembrolizumab+in+Patients+with+Advanced+Solid+Tumors%3A+The+Phase+1b+Data+Report&amp;index=2&amp;md5=06978c4920ef9df26565459945d3b9de\">Safety, Pharmacokinetics, Pharmacodynamics Profiles and Preliminary Antitumor Activity of Phase 1b\/2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab in Patients with Advanced Solid Tumors: The Phase 1b Data Report<br \/>\n<\/a><br \/>Lead Author: Aung Naing, MD, The University of Texas MD Anderson Cancer Center<br \/>\n<br \/>Abstract Number: 2594<br \/>\n<br \/>Poster Session: Developmental Therapeutics\u2014Immunotherapy, on demand starting at 9:00am ET, June 4, 2021\n<\/p>\n<p>\nTitle: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetinglibrary.asco.org%2Frecord%2F196604%2Fabstract&amp;esheet=52432801&amp;newsitemid=20210520005304&amp;lan=en-US&amp;anchor=A+phase+I%2FII+study+to+evaluate+the+safety+and+efficacy+of+a+novel+long-acting+interleukin-7%2C+NT-I7%2C+for+patients+with+newly+diagnosed+high-grade+gliomas+after+chemoradiotherapy%3A+the+interim+result+of+the+phase+I+data&amp;index=3&amp;md5=00f3ad0c8f63eeffa1cb200029de90d9\">A phase I\/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: the interim result of the phase I data<br \/>\n<\/a><br \/>Lead Author: Jian Li Campian, MD, PhD, Washington University School of Medicine in St. Louis\/Siteman Cancer Center<br \/>\n<br \/>Abstract Number: 2040<br \/>\n<br \/>Poster Session: Central Nervous System Tumors, on demand starting at 9:00am ET, June 4, 2021\n<\/p>\n<p>\nKEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, N.J., USA.\n<\/p>\n<p><b>About NT-I7<\/b><\/p>\n<p>\nNT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may provide clinical benefit. IL-7 is a fundamental cytokine for na\u00efve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). In clinical trials to date, NT-I7 has exhibited favorable PK\/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.\n<\/p>\n<p><b>About NeoImmuneTech<\/b><\/p>\n<p>\nNeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune\/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.neoimmunetech.com&amp;esheet=52432801&amp;newsitemid=20210520005304&amp;lan=en-US&amp;anchor=www.neoimmunetech.com.&amp;index=4&amp;md5=343058794494bff7fe5f92fcc540f9fa\">www.neoimmunetech.com.<\/a><\/p>\n<p><b>Forward-looking Statements<\/b><\/p>\n<p>\nThe statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the \u201cCompany\u201d) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company\u2019s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.\n<\/p>\n<p>\nSome of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties, and is subject to change based on various factors.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210520005304\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210520005304\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<br \/><\/b>Hayoung Lee<br \/>\n<br \/>+82 31 709 5858<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:hylee@neoimmunetech.com\">hylee@neoimmunetech.com<\/a><\/p>\n<p><b>Media:<br \/>\n<br \/><\/b>MacDougall<br \/>\n<br \/>Carolyn Noyes<br \/>\n<br \/>+1 781 235 3060<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cnoyes@macbiocom.com\">cnoyes@macbiocom.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Maryland United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210520005304\/en\/686975\/3\/NeoImmuneTech-Logo-Full-Color-RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211;NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company\u2019s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021. The data come from clinical studies evaluating NT-I7, a novel long-acting human IL-7, 1. in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) as a treatment for advanced solid tumors, and 2. given concurrently with adjuvant chemotherapy in patients with high-grade gliomas. Details related to the poster presentations are as follows: Title: Safety, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-496219","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211;NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company\u2019s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021. The data come from clinical studies evaluating NT-I7, a novel long-acting human IL-7, 1. in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) as a treatment for advanced solid tumors, and 2. given concurrently with adjuvant chemotherapy in patients with high-grade gliomas. Details related to the poster presentations are as follows: Title: Safety, &hellip; Continue reading &quot;NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-20T11:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2021-05-20T11:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":723,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-05-20T11:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting - Market Newsdesk","og_description":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211;NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company\u2019s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021. The data come from clinical studies evaluating NT-I7, a novel long-acting human IL-7, 1. in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) as a treatment for advanced solid tumors, and 2. given concurrently with adjuvant chemotherapy in patients with high-grade gliomas. Details related to the poster presentations are as follows: Title: Safety, &hellip; Continue reading \"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-20T11:03:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting","datePublished":"2021-05-20T11:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":723,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/","name":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-05-20T11:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005304r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoimmunetech-to-present-two-posters-at-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=496219"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496219\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=496219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=496219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=496219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}